Liver repopulation for the treatment of metabolic diseases
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Orthotopic liver transplantation is the treatment of choice for several inborn errors of metabolism. Unfortunately, the supply of donor organs is limiting and therefore many patients cannot benefit from this therapy. In contrast, hepatocyte transplantation could potentially overcome the shortage in donor livers by use of cells from a single donor for multiple recipients. In classic hepatocyte transplantation, however, only 1% of the liver mass or less can be replaced by donor cells. Recently, though, it has been shown in animal models that >90% of host hepatocytes can be replaced by a small number of transplanted donor cells in a process we term ‘therapeutic liver repopulation’. This phenomenon is analogous to repopulation of the haematopoietic system after bone marrow transplantation. Liver repopulation occurs when transplanted cells have a growth advantage in the setting of damage to recipient liver cells. It has been discovered that transplanted cells from extrahepatic sources such as the adult pancreas or bone marrow can also be used for liver repopulation. Because bone marrow donors are widely available, this finding raises the hope of therapeutic application of these cells in the future. Here, the current knowledge regarding therapeutic liver repopulation and the hopeful implications for treatment of liver diseases will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Purified hematopoietic stem cells can differentiate into hepatocytes in vivo
Lagasse, E., Connors, H., Al-Dhalimy, M., Reitsma, M., Dohse, M., Osborne, L., Wang, X., Finegold, M., Weissman, I. L., & Grompe, M. (2000) · Nature Medicine · doi:10.1038/81326 · Cited by 2,314
Self-citationOverturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549
Self-citationOn the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447 · cited 2×
“Tyrosinaemia I (HT I) is an inborn error of metabolism due to de¢ciency of fumarylacetoacetate hydrolase (FAH; EC 3.7.1.2), the ¢nal step in tyrosine catabolism (Lindblad et al 1977).”
BackgroundInfluentialGrompe, M., al-Dhalimy, M., Finegold, M., Ou, C. N., Burlingame, T., Kennaway, N. G., & Soriano, P. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2298 · Cited by 355 · cited 1×
“Liver repopulation with transplanted hepatocytes Because of the spontaneous emergence of revertant nodules in human HT I, the concept of therapeutic liver repopulation was then explored in a murine model of FAH de¢ciency (Grompe et al 1993).”
BackgroundSelf-citationGrompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., Torres-Ramos, C. A., Ou, C.-N., & Finegold, M. (1995) · Nature Genetics · doi:10.1038/ng0895-453 · Cited by 312 · cited 2×
“FAA itself is primarily responsible for much of the local tissue damage, leading to death of hepatocytes, proximal renal tubular cells and other cells (Grompe et al 1995; Kubo et al 1998; Lindblad et al 1977; Sun et al 2000).”
BackgroundSelf-citationDe Vree, J. M. L., Ottenhoff, R., Bosma, P. J., Smith, A. J., Aten, J., & Oude Elferink, R. P. J. (2000) · Gastroenterology · doi:10.1053/gast.2000.20222 · Cited by 186 · cited 1×
“A preliminary report of partial liver repopulation in a murine model of progressive familial intrahepatic cholestasis represents another example of how therapeutic cell transplantation might be conducted (De Vree et al 2000).”
BackgroundSelf-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 2×
“Spontaneous liver repopulation in HT I patients Recently an important observation was made in human patients with HT I. FAH immunostaining of livers removed at transplantation revealed the presence of a mosaic of antibody-positive and -negative hepatic tissue (Kvittingen et al 1993).”
Background
Cited by
Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers
Aurich, I., Mueller, L. P., Aurich, H., Luetzkendorf, J., Tisljar, K., Dollinger, M. M., Schormann, W., Walldorf, J., Hengstler, J. G., Fleig, W. E., et al. (2007) · Gut · doi:10.1136/gut.2005.090050 · Cited by 314
Sgodda, M., Aurich, H., Kleist, S., Aurich, I., König, S., Dollinger, M. M., Fleig, W. E., & Christ, B. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.05.020 · Cited by 186
The pathophysiology and treatment of hereditary tyrosinemia type 1
Grompe, M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19035 · Cited by 167
Self-citationEffect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec
Larochelle, J., Alvarez, F., Bussières, J.-F., Chevalier, I., Dallaire, L., Dubois, J., Faucher, F., Fenyves, D., Goodyer, P., Grenier, A., et al. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.05.022 · Cited by 137
“Will hepatocyte replacement or gene therapy supersede nitisinone treatment? Promising results have been obtained in FAH-deficient mice [21].”
Background
Metadata
- Authors
- Grompe, M.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2001-04
- Volume
- 24
- Issue
- 2
- Pages
- 231-244
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W160728561
- Cited by
- 56
- References
- 8
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.